Daily Sepsis Research Analysis
Three studies advance sepsis science across translational therapy, mechanism, and predictive analytics. A multifunctional hyaluronic acid-based nanocarrier enhanced vancomycin efficacy and survival in MRSA sepsis mice, a mechanistic study identified Erbin as a regulator of tissue factor via Ras/Raf in sepsis coagulopathy, and a LightGBM model modestly outperformed qSOFA for mortality prediction using rapidly obtainable features.
Summary
Three studies advance sepsis science across translational therapy, mechanism, and predictive analytics. A multifunctional hyaluronic acid-based nanocarrier enhanced vancomycin efficacy and survival in MRSA sepsis mice, a mechanistic study identified Erbin as a regulator of tissue factor via Ras/Raf in sepsis coagulopathy, and a LightGBM model modestly outperformed qSOFA for mortality prediction using rapidly obtainable features.
Research Themes
- Nanomedicine against antimicrobial-resistant sepsis
- Mechanisms of sepsis-associated coagulopathy
- AI-enabled early mortality risk stratification
Selected Articles
1. Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.
A hyaluronic acid-lysine–based, pH-responsive hybrid nanostructured lipid carrier enhanced vancomycin activity against S. aureus and MRSA, reduced MICs (up to eightfold at acidic pH), and improved survival in an MRSA sepsis mouse model. The platform also inhibited MRSA efflux pumps, ROS, and LPS-induced hyperinflammation while targeting TLR2/4.
Impact: Demonstrates a multifunctional nanocarrier that simultaneously enhances antibiotic potency, targets innate immune receptors, and improves survival in vivo—addressing AMR, a central barrier in sepsis care.
Clinical Implications: If translated to humans, such carriers could enable lower vancomycin doses with superior efficacy against MRSA sepsis, potentially reducing toxicity and overcoming resistance. The pH-responsive, TLR-targeting design may improve delivery to infected, acidic microenvironments.
Key Findings
- VCM-HNLCs reduced MICs versus free vancomycin (twofold at neutral pH; four- to eightfold at pH 6.0 over 24–72 h).
- Nanocarriers demonstrated TLR2/4 binding (validated by microscale thermophoresis).
- In an MRSA-induced sepsis mouse model, VCM-HNLCs significantly decreased bacterial burden and improved survival compared with free VCM.
- VCM-HNLCs inhibited MRSA efflux pumps, ROS, and LPS-induced hyperinflammation, indicating multimodal action.
Methodological Strengths
- Combined in vitro characterization (size, PDI, zeta, encapsulation, hemolysis/cytotoxicity) with in vivo efficacy in a sepsis model.
- Mechanistic assays (TLR2/4 binding, efflux pump and ROS modulation) support biological plausibility.
Limitations
- Preclinical study without human data; pharmacokinetics, safety, and immunogenicity in humans remain unknown.
- Exact animal sample sizes and statistical details are not specified in the abstract.
Future Directions: Conduct dose-ranging pharmacokinetics/toxicology and efficacy studies in larger animal models; evaluate synergy with other antibiotics; and initiate early-phase clinical trials in MRSA bacteremia/sepsis.
INTRODUCTION: The application of biomimetic and stimuli-responsive nanocarriers displays considerable promise in improving the management of bacterial sepsis and overcoming antimicrobial resistance. Therefore, the study aimed to synthesize a novel hyaluronic acid-lysine conjugate (HA-Lys) and to utilize the attributes of the synthesized HA-Lys with Tocopherol succinate (TS) and Oleylamine (OLA) in the formulation of multifunctional biomimetic pH-responsive HNLCs loaded with vancomycin (VCM-HNLCs), to combat bacterial sepsis. METHODS: A novel hyaluronic acid-lysine conjugate (HA-Lys) was synthesized and characterized using FTIR and RESULTS: The VCM-HNLCs, produced via hot homogenization ultrasonication, exhibited particle size (PS), polydispersity index (PDI), zeta potential (ZP), and encapsulation efficiency (EE%) of 110.77 ± 1.692 nm, 0.113 ± 0.022, - 2.92 ± 0.210 mV, and 76.27 ± 1.200%, respectively. In vitro, biocompatibility was proven by hemolysis and cytotoxicity studies. The VCM-HNLCs demonstrated targetability to human Toll-like receptors (TLR 2 and 4) as validated by microscale thermophoresis (MST). VCM-HNLCs showed a twofold reduction in MIC values at physiological pH compared to the bare VCM against S. aureus and MRSA for 48 h. While at pH 6.0, MIC values were reduced by fourfold in the first 24 h and by eightfold in the subsequent 48 and 72 h against tested strains. Furthermore, VCM-HNLCs showed inhibitory effects against MRSA efflux pumps, reactive oxygen species (ROS), and lipopolysaccharide (LPS)-induced hyperinflammation. In an MRSA-induced sepsis mice model, VCM-HNLCs demonstrated superior efficacy compared to free VCM, significantly eliminated bacteria and improved survival rates. CONCLUSIONS: Overall, these results highlight the potential of VCM-HNLCs as novel multifunctional nanocarriers to combat antimicrobial resistance (AMR) and enhance sepsis outcomes.
2. Erbin Regulates Tissue Factors Through Ras/Raf Pathway in Coagulation Disorders in Sepsis.
Using CLP murine sepsis and LPS-stimulated macrophages, the authors show Erbin restrains coagulation by limiting macrophage tissue factor release via Ras/Raf signaling. Erbin deficiency increased coagulation activation in vivo, positioning Erbin as a potential target for sepsis-associated coagulopathy.
Impact: Identifies a mechanistic link between Erbin and tissue factor regulation in sepsis, clarifying macrophage-driven coagulopathy and suggesting a tractable signaling axis (Ras/Raf) for intervention.
Clinical Implications: Targeting Erbin or downstream Ras/Raf signaling could modulate tissue factor release and coagulation activation in sepsis, providing a path to adjunctive therapies for sepsis-associated coagulopathy.
Key Findings
- Erbin deficiency enhanced coagulation activation in vivo in CLP-induced sepsis.
- Erbin knockout macrophages increased tissue factor secretion via activation of the Ras/Raf pathway.
- Pharmacologic MEK inhibition and molecular assays (WB, Co-IP, IF, qPCR, ELISA) delineated the signaling mechanism linking Erbin to TF regulation.
- Inflammation indices correlated with coagulation indices, supporting immune–coagulation crosstalk.
Methodological Strengths
- Integrated in vitro macrophage signaling assays with an in vivo CLP sepsis model.
- Multiple orthogonal techniques (WB, Co-IP, IF, qPCR, ELISA, histology) strengthen mechanistic inference.
Limitations
- Preclinical model; lack of validation in human sepsis samples.
- The abstract does not specify effect sizes or detailed coagulation parameters (e.g., thrombin–antithrombin levels).
Future Directions: Validate Erbin–Ras/Raf–TF axis in human sepsis cohorts; test pharmacologic modulation of this pathway in preclinical sepsis models; explore cell-specific targeting to macrophages.
BACKGROUND: Sepsis, as a clinically critical disease, usually induces coagulation disorders. It has been reported that ERBB2 Interacting Protein (Erbin) is involved in the development of various inflammatory diseases, and macrophages are involved in the regulation of coagulation disorders in sepsis. However, the role of Erbin in coagulation disorders in sepsis and the relationship between Erbin and macrophage regulation of coagulation function are still unclear. METHODS: At the cellular level, macrophages were treated with lipopolysaccharide (LPS) or MEK inhibitor (PD98059), protein expression levels were detected by Western blot, co-immunoprecipitation (Co-IP), and immunofluorescence, mRNA expression levels were detected by quantitative real-time polymerase chain reaction (qPCR), and the concentration of tissue factor (TF) in cell supernatant was detected by enzyme linked immunosorbent assay (ELISA). At the animal level, the cecal ligation and perforation (CLP) model was constructed in mice, and the inflammatory response and coagulation disorder of mice were observed by hematoxylin-eosin (HE) staining, immunohistochemistry, ELISA, and automatic hemagglutination analyzer. The protein and mRNA expression level were detected by Western blot and qPCR. Pearson linear correlation analysis was used to analyze the correlation between the inflammation index and the coagulation function index. RESULTS: We confirmed that the Erbin is involved in the regulation of coagulation function by macrophages and plays a role in the coagulation disorder of sepsis. In vivo studies have shown that mice with Erbin deletion have more obvious enhanced coagulation function, and in vitro studies have shown that Erbin knockout mediated macrophage secretion of TF by activating the Ras/Raf pathway. CONCLUSION: Erbin reduces the coagulation activation by inhibiting TF release from macrophages.
3. Improving sepsis mortality prediction with machine learning: A comparative study of advanced classifiers and performance metrics.
On MIMIC-IV data, LightGBM achieved AUC 0.79 and PRAUC 0.44, modestly outperforming qSOFA and other classifiers. Dynamic updating and hyperparameter tuning improved discrimination, and SHAP analysis provided interpretable feature importance for clinical triage.
Impact: Demonstrates practically oriented, interpretable ML that slightly surpasses qSOFA and emphasizes dynamic updating, a relevant direction for prehospital sepsis risk stratification.
Clinical Implications: Ambulance and ED teams could use dynamically updating ML tools to identify high-risk sepsis patients earlier than with simple scores, potentially prioritizing monitoring, antibiotics, and transfer decisions.
Key Findings
- LightGBM achieved the highest AUC (0.79) and PRAUC (0.44), outperforming qSOFA (AUC 0.76, PRAUC 0.40).
- Dynamic model updating and tuning improved performance over the base model (AUC 0.79 vs 0.76; PRAUC 0.44 vs 0.39).
- SHAP-based feature importance provides interpretability to support clinical prioritization.
Methodological Strengths
- Head-to-head comparison of 11 ML algorithms with standardized metrics (AUC, PRAUC).
- Use of SHAP for interpretability and implementation of dynamic updating to reflect real-time data.
Limitations
- Retrospective single-dataset analysis (MIMIC-IV) without external, prospective prehospital validation.
- Ambulance applicability is inferred; features may differ in real-world EMS settings.
Future Directions: Prospective external validation in EMS/ED settings; assess calibration, clinical utility (decision-curve analysis), and workflow integration; explore federated learning for multi-site deployment.
BACKGROUND: High sepsis mortality rates pose a serious global health problem. Machine learning is a promising technique with the potential to improve mortality prediction for this disease in an accurate and timely manner. OBJECTIVES: This study aimed to develop a model capable of rapidly and accurately predicting sepsis mortality using data that can be quickly obtained in an ambulance, with a focus on practical application during ambulance transport. MATERIAL AND METHODS: Data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) dataset were used to compare the performance of 11 machine learning algorithms against the widely utilized quick Sequential Organ Failure Assessment (qSOFA) score. A dynamic updating model was implemented. Performance was evaluated using area under the curve (AUC) and precision-recall area under the curve (PRAUC) scores, and feature importance was assessed with SHapley Additive exPlanations (SHAP) values. RESULTS: The light gradient boosting machine (LightGBM) model achieved the highest AUC (0.79) and PRAUC (0.44) scores, outperforming the qSOFA score (AUC = 0.76, PRAUC = 0.40). The LightGBM also achieved the highest PRAUC (0.44), followed by Optuna_LightGBM (0.43) and random forest (0.42). The dynamically updated and tuned model further improved performance metrics (AUC = 0.79, PRAUC = 0.44) compared to the base model (AUC = 0.76, PRAUC = 0.39). Feature importance analysis offers clinicians insights for prioritizing patient assessments and interventions. CONCLUSIONS: The LightGBM-based model demonstrated superior performance in predicting sepsis-related mortality in an ambulance setting. This study underscores the practical applicability of machine learning models, addressing the limitations of previous research, and highlights the importance of real-time updates and hyperparameter tuning in optimizing model performance.